AI Article Synopsis
- A retrospective study evaluated the effectiveness of interferon-α (IFN-α) as maintenance therapy in 84 patients with favorable-risk acute myeloid leukemia (AML), comparing 42 patients who received IFN-α to 42 control patients who did not.
- The findings indicated that the IFN-α group had significantly higher 4-year relapse-free survival (86.8%) and overall survival (94.4%) rates compared to the control group (55.7% and 76.4%, respectively).
- Cox regression analysis showed that IFN-α treatment was the only independent factor contributing positively to relapse-free survival, suggesting it may help prevent relapse in favorable-risk AML after chemotherapy.
Article Abstract
To evaluate the efficacy of interferon-α (IFN-α) as maintenance therapy in patients with favorable-risk acute myeloid leukemia (AML), this retrospective study enrolled 84 patients with favorable-risk AML: 42 patients who received IFN-α maintenance therapy and 42 patients who did not (control). The median follow-up time and duration of IFN-α treatment was 26 (6-54) months and 18 (2-24) months, respectively. The 4-year estimated relapse-free survival (RFS) after the last consolidation chemotherapy was 86.8% (95% confidence interval (CI), 75.8-97.8%) in the IFN-α group and 55.7% (95% CI, 37.2-74.3%) in the control group (=.007). The 4-year estimated overall survival was 94.4% (95% CI, 86.8-102%) and 76.4% (95% CI, 61.9-90.9%) in IFN-α and control groups, respectively (=.040). The Cox regression analysis showed that IFN-α treatment was the only independent factor affecting RFS (=.004). Maintenance therapy with IFN-α may prevent relapse in favorable-risk AML after consolidation chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.1948027 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!